Skip to main content

Table 2 Changes of drug sensitivity in 88 treatment-failure HIV/AIDS cases

From: Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China

Drugs/Frequency

Grade of DR(N/%)

Susceptible

Potential resistance

Low-level resistance

Intermediate resistance

High-level resistance

3TC

 T1

72 (81.82)

16 (18.18)

 T2

70 (79.55)

18 (20.45)

 T3

69 (78.41)

1 (1.14)

18 (20.45)

AZT

 T1

83 (94.32)

1 (1.14)

1 (1.14)

3 (3.41)

 T2

77 (87.50)

3 (3.41)

1 (1.14)

4 (4.55)

3 (3.41)

 T3

75 (85.23)

4 (4.55)

2 (2.27)

2 (2.27)

5 (5.68)

D4T

 T1

82 (93.18)

2 (2.27)

1 (1.14)

3 (3.41)

 T2

75 (85.23)

3 (3.41)

3 (3.41)

4 (4.55)

3 (3.41)

 T3

72 (81.82)

4 (4.55)

3 (3.41)

3 (3.41)

6 (6.82)

TDF

 T1

81 (92.05)

3 (3.41)

1 (1.14)

3 (3.41)

 T2

82 (93.18)

2 (2.27)

1 (1.14)

3 (3.41)

 T3

78 (88.64)

5 (5.68)

2 (2.27)

3 (3.41)

EFV

 T1

51 (57.95)

6 (6.82)

3 (3.41)

8 (9.09)

20 (22.73)

 T2

50 (56.82)

6 (6.82)

2 (2.27)

9 (10.23)

21 (23.86)

 T3

52 (59.09)

6 (6.82)

1 (1.14)

7 (7.95)

22 (25.00)

ETR

 T1

61 (69.32)

13 (14.77)

6 (6.82)

7 (7.95)

1 (1.14)

 T2

58 (65.91)

11 (12.50)

5 (5.68)

10 (11.36)

4 (4.55)

 T3

57 (64.77)

13 (14.77)

4 (4.55)

9 (10.23)

5 (5.68)

NVP

 T1

53 (60.23)

5 (5.68)

1 (1.14)

2 (2.27)

27 (30.68)

 T2

51 (57.95)

5 (5.68)

1 (1.14)

2 (2.27)

29 (32.95)

 T3

51 (57.95)

6 (6.82)

1 (1.14)

1 (1.14)

29 (32.95)

LPV/r

 T1

87 (98.86)

1 (1.14)

 T2

85 (96.59)

1 (1.14)

2 (2.27)

 T3

84 (95.45)

1 (1.14)

2 (2.27)

  1. T1: First detection, T2, T3 and the like